No AI summary available for this article.
Why It Matters
Vijay Pande — who left a16z's roughly $4 billion biotech practice last year to start the much smaller, AI-native VZVC — talks about why biology is finally shifting from a "discovery" science to an "engineering" one, why clinical trials are still brutally expensive, and why he thinks open, shared datasets (not walled-off ones) are what will actually let AI transform medicine.
Provenance
Discovered via RSS / Blogs and published by TechCrunch.
Original description
Vijay Pande — who left a16z's roughly $4 billion biotech practice last year to start the much smaller, AI-native VZVC — talks about why biology is finally shifting from a "discovery" science to an "engineering" one, why clinical trials are still brutally expensive, and why he thinks open, shared datasets (not walled-off ones) are what will actually let AI transform medicine.
Discovered via RSS / Blogs
Publisher feeds and independent blogs from across the AI ecosystem.
Publisher: techcrunch.com
ID: https://techcrunch.com/?p=3156771 · Indexed 1 day ago